This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/New_Zealand/hero_tile_video.mp4

Product Update

LAMICTAL (lamotrigine 25mg, 50mg, 100mg tablet) will continue to be available in New Zealand for private purchase from 1 Oct 2019

Welcome to GSKpro!

Access educational events, important product updates and patient support materials.

Product Update

LAMICTAL (lamotrigine 25mg, 50mg, 100mg tablet) will continue to be available in New Zealand for private purchase from
1 Oct 2019

More details

View our products

View our products

Find comprehensive information on our products including resources for patients.

Expert perspectives

Expert perspectives

By sharing our knowledge, we hope we can ultimately improve the lives of patients.  To do that we’ve developed the GSK Portal so healthcare professionals can have easy access to all our resources, tools, advice, opinion and news.

Lamictal (lamotrigine) is a prescription medicine, for adjunctive therapy in the treatment of epilepsy, for partial and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome; for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes. Lamictal is a fully funded medicine without restriction and is available in 2mg, 5mg, 25mg, 50mg and 100mg tablets. Before prescribing Lamictal, please review the Data Sheet available from www.medsafe.govt.nz for information on dosage, contraindications, precautions, interactions and adverse events.